Antibody responses to influenza a H1N1 vaccine compared to the circulating strain in influenza vaccine recipients during the 2013/2014 season in North America

2016 ◽  
Vol 83 ◽  
pp. 56-60 ◽  
Author(s):  
Michelle A. Barron ◽  
Daniel N. Frank ◽  
David Claypool ◽  
Diana Ir ◽  
Mariangeli F. Ning ◽  
...  
Keyword(s):  
North America ◽  
Influenza Vaccine ◽  
Influenza A ◽  
Antibody Responses ◽  
H1n1 Vaccine ◽  
Influenza A H1n1

Impact of the type of seasonal influenza vaccine on immune responses to the 2009 pandemic influenza A (H1N1) vaccine

Vaccine ◽  
2011 ◽  
Vol 29 (50) ◽  
pp. 9294-9295 ◽  
Author(s):  
Nancy F. Crum-Cianflone ◽  
Erik Iverson ◽  
Gabriel Defang
Keyword(s):  
Immune Responses ◽  
Influenza Vaccine ◽  
Pandemic Influenza ◽  
Influenza A ◽  
Seasonal Influenza ◽  
H1n1 Vaccine ◽  
Seasonal Influenza Vaccine ◽  
Influenza A H1n1

AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice

Vaccine ◽  
2010 ◽  
Vol 28 (18) ◽  
pp. 3076-3079 ◽  
Author(s):  
Catherine Caillet ◽  
Fabienne Piras ◽  
Marie-Clotilde Bernard ◽  
Aymeric de Montfort ◽  
Florence Boudet ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Pandemic Influenza ◽  
Influenza A ◽  
Seasonal Influenza ◽  
Antibody Responses ◽  
Seasonal Influenza Vaccine ◽  
Influenza A H1n1

Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents

Vaccine ◽  
2011 ◽  
Vol 29 (8) ◽  
pp. 1677-1682 ◽  
Author(s):  
Susanna Esposito ◽  
Laura Tagliaferri ◽  
Cristina Daleno ◽  
Antonia Valzano ◽  
Irene Picciolli ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Children And Adolescents ◽  
Pandemic Influenza ◽  
Influenza A ◽  
Seasonal Influenza ◽  
H1n1 Vaccine ◽  
Seasonal Influenza Vaccine ◽  
Influenza A H1n1

scholarly journals CD4+ T-Cell Expansion Predicts Neutralizing Antibody Responses to Monovalent, Inactivated 2009 Pandemic Influenza A(H1N1) Virus Subtype H1N1 Vaccine

2012 ◽  
Vol 207 (2) ◽  
pp. 297-305 ◽  
Author(s):  
Jennifer L. Nayak ◽  
Theresa F. Fitzgerald ◽  
Katherine A. Richards ◽  
Hongmei Yang ◽  
John J. Treanor ◽  
...  
Keyword(s):  
Pandemic Influenza ◽  
Cell Expansion ◽  
Influenza A ◽  
H1n1 Virus ◽  
Neutralizing Antibody ◽  
Antibody Responses ◽  
Cd4 T Cell ◽  
H1n1 Vaccine ◽  
Influenza A H1n1 ◽  
Virus Subtype

scholarly journals A Prospective Study of the Factors Shaping Antibody Responses to the AS03‐Adjuvanted Influenza A/H1N1 Vaccine in Cancer Outpatients

2012 ◽  
Vol 17 (3) ◽  
pp. 436-445 ◽  
Author(s):  
Andreas F. Hottinger ◽  
Anne‐Claude C. George ◽  
Michael Bel ◽  
Laurence Favet ◽  
Christophe Combescure ◽  
...  
Keyword(s):  
Prospective Study ◽  
Influenza A ◽  
Antibody Responses ◽  
H1n1 Vaccine ◽  
Influenza A H1n1 ◽  
A Prospective Study

scholarly journals Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults

Vaccine ◽  
2011 ◽  
Vol 29 (17) ◽  
pp. 3183-3191 ◽  
Author(s):  
Nancy F. Crum-Cianflone ◽  
Erik Iverson ◽  
Gabriel Defang ◽  
Patrick J. Blair ◽  
Lynn E. Eberly ◽  
...  
Keyword(s):  
Pandemic Influenza ◽  
Influenza A ◽  
Antibody Responses ◽  
H1n1 Vaccine ◽  
Influenza A H1n1

scholarly journals Influenza Vaccine Effectiveness and Waning Effect in Hospitalized Older Adults. Valencia Region, Spain, 2018/2019 Season

2021 ◽  
Vol 18 (3) ◽  
pp. 1129
Author(s):  
Ainara Mira-Iglesias ◽  
F. Xavier López-Labrador ◽  
Javier García-Rubio ◽  
Beatriz Mengual-Chuliá ◽  
Miguel Tortajada-Girbés ◽  
...  
Keyword(s):  
Older Adults ◽  
Influenza Vaccine ◽  
Influenza A ◽  
Vaccine Effectiveness ◽  
Surveillance Network ◽  
Adjuvanted Vaccine ◽  
Clinical Registries ◽  
Populations At Risk ◽  
Influenza A H1n1 ◽  
Hospitalized Older Adults

Influenza vaccination is annually recommended for specific populations at risk, such as older adults. We estimated the 2018/2019 influenza vaccine effectiveness (IVE) overall, by influenza subtype, type of vaccine, and by time elapsed since vaccination among subjects 65 years old or over in a multicenter prospective study in the Valencia Hospital Surveillance Network for the Study of Influenza and other Respiratory Viruses (VAHNSI, Spain). Information about potential confounders was obtained from clinical registries and/or by interviewing patients and vaccination details were only ascertained by registries. A test-negative design was performed in order to estimate IVE. As a result, IVE was estimated at 46% (95% confidence interval (CI): (16%, 66%)), 41% (95% CI: (−34%, 74%)), and 45% (95% CI: (7%, 67%)) against overall influenza, A(H1N1)pdm09 and A(H3N2), respectively. An intra-seasonal not relevant waning effect was detected. The IVE for the adjuvanted vaccine in ≥75 years old was 45% (2%, 69%) and for the non-adjuvanted vaccine in 65–74 years old was 59% (−16%, 86%). Thus, our data revealed moderate vaccine effectiveness against influenza A(H3N2) and not significant against A(H1N1)pdm09. Significant protection was conferred by the adjuvanted vaccine to patients ≥75 years old. Moreover, an intra-seasonal not relevant waning effect was detected, and a not significant IVE decreasing trend was observed over time.

Sign in / Sign up

Export Citation Format

Share Document